- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Coiled Therapeutics - Life Sciences Investor Forum | - | RNS | ||
| Do | Coiled Therapeutics - Proactive One2One Investor Forum | - | RNS | ||
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Coiled Therapeutics - Grant of Share Options | 1 | RNS | ||
| Mi | Coiled Therapeutics beruft renommierte Onkologen in medizinischen Beirat | - | Investing.com Deutsch | ||
| Mi | Coiled Therapeutics establishes medical advisory board | 1 | Investing.com | ||
| Mi | Coiled Therapeutics - Establishment of Medical Advisory Board | - | RNS | ||
| 08.06. | Coiled Therapeutics beruft Professor Ozgur Sahin in den wissenschaftlichen Beirat | 3 | Investing.com Deutsch | ||
| 08.06. | Coiled Therapeutics appoints Ozgur Sahin as scientific advisor | 1 | Investing.com | ||
| 08.06. | Coiled Therapeutics - Appointment of Ozgur Sahin as Scientific Advisor | - | RNS | ||
| 29.05. | Coiled Therapeutics - Issue of Equity | - | RNS | ||
| 27.05. | Coiled Therapeutics - Notice of Annual General Meeting | - | RNS | ||
| 19.05. | Coiled Therapeutics shares rise as cross trading begins in New York | 1 | Alliance News | ||
| 19.05. | Coiled Therapeutics startet Handel am US-Markt OTCQB | 1 | Investing.com Deutsch | ||
| 19.05. | Coiled Therapeutics begins trading on US OTCQB market | 2 | Investing.com | ||
| 19.05. | Coiled Therapeutics - Commencement of Trading on US OTCQB Venture Market | - | RNS | ||
| 07.05. | Coiled Therapeutics präsentiert auf New Yorker Accelerator-Programm | 1 | Investing.com Deutsch | ||
| 07.05. | Coiled Therapeutics presents at NY accelerator program | 1 | Investing.com | ||
| 07.05. | Coiled Therapeutics - Attendance at Endless Frontier Labs 2026 | - | RNS | ||
| 07.05. | Coiled Therapeutics - Appointment of Non-Executive Director | - | RNS | ||
| 06.05. | Coiled Therapeutics reports strategic shift to oncology assets | 1 | Investing.com |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,54 | -0,01 % | Pharma-Milliardendeal: AbbVie kauft Biotech-Hoffnung - Übernahmeziel schießt um fast 50 % hoch! | © Foto: Nikos Pekiaridis - NurPhotoAbbVie übernimmt Apogee Therapeutics für rund 10,9 Milliarden US-Dollar. Der Deal soll das Immunologiegeschäft stärken und neue Wachstumstreiber schaffen.AbbVie sichert... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 99,45 | 0,00 % | Truist reiterates Kymera stock Buy rating after AbbVie deal | ||
| CG ONCOLOGY | 66,25 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | -0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | +0,21 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| IMMUNOVANT | 38,100 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| ERASCA | 15,065 | -0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 303,08 | -0,10 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| DISC MEDICINE | 70,80 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ABSCI | 8,420 | +0,24 % | Leerink Starts Coverage on Absci Corporation (ABSI) | ||
| ENLIVEN THERAPEUTICS | 45,960 | 0,00 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| STRUCTURE THERAPEUTICS | 45,510 | 0,00 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 17,280 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,860 | +0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,430 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen |
COILED THERAPEUTICS PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,008 (+8,05 %) liegt der Kurs bei 0,103 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COILED THERAPEUTICS PLC finden Sie auf Wallstreet Online.